Lilly has unveiled promising results from a Phase III study of a lung cancer treatment which showed improved overall survival in patients. The news is a welcome relief to Lilly, which has endured a ...

Eli Lilly and Company’s LLY announced that a late-stage study evaluating its already approved cancer drug, Cyramza for the second-line treatment of liver cancer met the primary as well as secondary ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against Novartis’ rival offering. Lilly’s Verzenio has proven its ability to prolong ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

(Reuters) - An experimental cancer drug developed by Eli Lilly and Co, touted by some to be the company's next blockbuster, significantly improved survival rates in lung cancer patients, sending the ...

Eli Lilly's CDK4/6 inhibitor Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative breast cancer, according the reveal of data from the ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...